Amgen (AMGN) Total Current Liabilities (2009 - 2026)
Amgen's quarterly Total Current Liabilities came in at $25.0 billion in Q1 2026, up 8.46% year-on-year from $23.0 billion in Q1 2025, and down 2.1% quarter-over-quarter from $25.5 billion in Q4 2025.
Amgen has reported Total Current Liabilities for 18 years, with the latest figure at $25.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 8.46% year-over-year to $25.0 billion; the trailing twelve-month figure through Mar 2026 stood at $25.0 billion (up 8.46% YoY), and the FY2025 full-year result was $25.5 billion, up 10.35% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $25.0 billion, down from $25.5 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $25.5 billion in Q4 2025, with the low at $12.6 billion in Q2 2022.
- Average Total Current Liabilities over 5 years is $19.0 billion, with a median of $19.7 billion recorded in 2024.
- Year-over-year, Total Current Liabilities decreased 13.49% in 2022 and jumped 38.68% in 2024.
- Tracing AMGN's Total Current Liabilities over 5 years: stood at $15.7 billion in 2022, then gained by 17.24% to $18.4 billion in 2023, then rose by 25.59% to $23.1 billion in 2024, then increased by 10.35% to $25.5 billion in 2025, then declined by 2.1% to $25.0 billion in 2026.
- The last three Total Current Liabilities figures came in at $25.0 billion (Q1 2026), $25.5 billion (Q4 2025), and $21.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 28.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.96 Bn |
| Dec 31, 2025 | 25.49 Bn |
| Sep 30, 2025 | 21.79 Bn |
| Jun 30, 2025 | 20.48 Bn |
| Mar 31, 2025 | 23.01 Bn |
| Dec 31, 2024 | 23.10 Bn |
| Sep 30, 2024 | 20.31 Bn |
| Jun 30, 2024 | 21.52 Bn |
| Mar 31, 2024 | 19.71 Bn |
| Dec 31, 2023 | 18.39 Bn |
| Sep 30, 2023 | 16.95 Bn |
| Jun 30, 2023 | 17.10 Bn |
| Mar 31, 2023 | 14.22 Bn |
| Dec 31, 2022 | 15.69 Bn |
| Sep 30, 2022 | 14.33 Bn |
| Jun 30, 2022 | 12.62 Bn |
| Mar 31, 2022 | 12.89 Bn |
| Dec 31, 2021 | 12.18 Bn |
| Sep 30, 2021 | 14.84 Bn |
| Jun 30, 2021 | 14.59 Bn |
| Mar 31, 2021 | 12.87 Bn |
| Dec 31, 2020 | 11.65 Bn |
| Sep 30, 2020 | 9.95 Bn |
| Jun 30, 2020 | 10.52 Bn |
| Mar 31, 2020 | 11.83 Bn |
| Dec 31, 2019 | 12.84 Bn |
| Sep 30, 2019 | 10.74 Bn |
| Jun 30, 2019 | 10.62 Bn |
| Mar 31, 2019 | 12.71 Bn |
| Dec 31, 2018 | 13.49 Bn |
| Sep 30, 2018 | 12.43 Bn |
| Jun 30, 2018 | 11.21 Bn |
| Mar 31, 2018 | 10.48 Bn |
| Dec 31, 2017 | 9.02 Bn |
| Sep 30, 2017 | 8.19 Bn |
| Jun 30, 2017 | 7.82 Bn |
| Mar 31, 2017 | 10.52 Bn |
| Dec 31, 2016 | 11.20 Bn |
| Sep 30, 2016 | 10.54 Bn |
| Jun 30, 2016 | 10.83 Bn |
| Mar 31, 2016 | 8.52 Bn |
| Dec 31, 2015 | 8.66 Bn |
| Sep 30, 2015 | 7.17 Bn |
| Jun 30, 2015 | 6.89 Bn |
| Mar 31, 2015 | 6.34 Bn |
| Dec 31, 2014 | 7.01 Bn |
| Sep 30, 2014 | 8.55 Bn |
| Jun 30, 2014 | 7.87 Bn |
| Mar 31, 2014 | 8.20 Bn |
| Dec 31, 2013 | 7.95 Bn |
| Sep 30, 2013 | 4.84 Bn |
| Jun 30, 2013 | 4.78 Bn |
| Mar 31, 2013 | 5.14 Bn |
| Dec 31, 2012 | 8.19 Bn |
| Sep 30, 2012 | 8.37 Bn |
| Dec 31, 2011 | 5.75 Bn |
| Mar 31, 2010 | 6.56 Bn |
| Dec 31, 2009 | 3.87 Bn |
| Sep 30, 2009 | 4.90 Bn |
| Jun 30, 2009 | 4.55 Bn |